AstraZeneca (AZN) said Wednesday Enhertu followed by paclitaxel, trastuzumab and pertuzumab or THP improved the pathologic complete response rate compared with standard of care in a phase 3 breast cancer study.
Pathologic complete response, or the absence of invasive cancer cells in the removed breast tissue and lymph nodes after treatment, is the primary endpoint of the study, the company said.
Achieving that response in early-stage HER2-positive breast cancer is linked to enhanced long-term outcomes, the company added.
The secondary endpoint of event-free survival wasn't mature at the time of analysis, but data showed an early positive trend for Enhertu followed by THP as well, the company said.
The company and Daiichi Sankyo agreed to jointly develop and commercialize Enhertu in 2019, AstraZeneca said.
Price: 70.12, Change: -0.14, Percent Change: -0.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。